Background: Intraepidermal nerve fiber density (IENFD) is considered a good diagnostic tool for small fiber neuropathy (SFN).
Investigating sensory symptoms can be a diagnostic challenge. When a neuropathy is considered, neurologic examination and nerve conduction studies generally do not reveal abnormalities if predominantly small fibers are affected. 1 There is no gold standard for diagnosing small fiber neuropathy (SFN), though a sensory neuropathy may present with small fiber involvement or indicate a disease causing pure small fiber dysfunction. 2 Typically, patients with SFN report burning pain in the extremities, combined with autonomic dysfunction, such as dry eyes, changes in sweating, and gastrointestinal and urogenital dysfunction. 3 Quantitative sensory testing such as temperature detection thresholds, sudomotor axon reflex, and cardiovascular autonomic testing are available techniques to determine small nerve fiber function. However, some tests have disadvantages, such as subjectivity, high burden for patients, or low sensitivity and specificity. 4 In SFN, loss of intraepidermal nerves is considered an objective diagnostic feature. 5 There are several potentially treatable illnesses that may cause SFN. Diabetes mellitus is the most frequent underlying disease, but several other metabolic, inflammatory, and hereditary disorders cause SFN. 2 Recently, SFN was demonstrated to occur in sarcoidosis. 6 Only a small sample of patients with sarcoidosis has been examined so far.
Determination of intraepidermal nerve fiber density (IENFD) is considered a reliable technique to assess loss and regeneration of small nerve fibers. Several techniques have been adopted; the most commonly used are bright field immunohistochemistry and indirect immunofluorescence on punch biopsies. [7] [8] [9] Reported interobserver/intraobserver variability is good. 10 The aims of the current study are to present normative IENFD values, stratified for age and sex, for a collaborative group (Maastricht, The Netherlands; Milan and Ferrara, Italy), and to examine the interobserver/intraobserver reliability and discriminatory validity of IENFD in a cohort of patients with sarcoidosis.
METHODS Participants. Healthy controls. Healthy controls were recruited from hospital personnel, from relatives and friends of patients, at sports accommodations, and at informal meetings for the elderly, in The Netherlands and Italy. Healthy individuals were stratified for age and sex, forming 6 age groups (20 -29, 30 -39, 40 -49, . . . up to 70 years and older) consisting of at least 15 men and 15 women each. Eligibility criteria were lucid consciousness, no neurologic symptoms, no history of alcohol misuse (defined as Ͼ4 IU/day), no use of drugs or history of diseases that may cause sensory deficit (e.g., chemotherapeutic agents in the past, malignancy, diabetes mellitus, thyroid dysfunction, renal failure, peripheral vascular disease, skin disorders), and normal findings at neurologic examination.
Patients. From October 2006 to June 2008, patients referred to the Maastricht Sarcoidosis Management Center, a referral center for sarcoidosis in The Netherlands, were screened for eligibility. Inclusion criteria for the study were age older than 18 years, no alcohol abuse, no use of immunosuppressant or neuropathy-causing drugs, no concomitant disease possibly causing SFN (normal laboratory findings for glucose, thyroid function, blood count, and renal and liver function tests), and a neurologic examination without signs of large fiber neuropathy or CNS involvement. Furthermore, nerve conduction findings (assessing median, peroneal, and tibial motor nerves, and median and sural sensory nerves under predefined conditions) had to be normal. All patients were diagnosed as having sarcoidosis in accordance with postulated diagnostic guidelines. 11 We only recruited therapy-naive patients or patients who had not received immuno-suppressive therapy in the 6 months before inclusion, because the effect of these medications on small nerve fibers is unknown.
Assessments. Skin biopsy. Published European guidelines on the use of skin biopsy in the diagnosis of SFN were used. 7 A 3-mm punch biopsy was performed under local anesthesia (1% lidocaine) 10 cm above the right lateral malleolus in all subjects. All biopsies were fixed in 2% paraformaldehyde-lysinesodiummetaperiodate and stored at Ϫ80°C in a cryoprotective solution (20% glycerol) before further processing. After cutting (Microm, HM560 Cryostar, Walldorf, Germany), the 50-mthick sections were immunostained using a free-floating method: after bleaching, the sections were blocked with goat serum, incubated with the panaxonal marker PGP 9.5 (Ultraclone, Wellow, Isle of Wight, UK), and secondary antibody (biotinylated antirabbit immunoglobulin G, Biozol, Eching, Germany). The reaction was then visualized after endogenous peroxidase blocking, with the Vectastain ABC kit and Vector SG substrate kit (Vector Laboratories, Burlingame, CA). Epidermal length was measured and sections were counted with bright field microscopy on a stereology workstation (Olympus BX50 with PlanApo objective 40ϫ [oil; NA ϭ 1.0], Tokyo, Japan, and stereology software Stereo-Investigator version 7.00.3, Micro-BrightField, Williston, VT), applying the established counting rules. 12 In brief, the rules state that to be counted, intraepidermal nerves have to cross or originate at the dermal-epidermal junction, and secondary branches and fragments are not counted. After fixing the specimens, at least 3 sections were analyzed under the light microscope. IENFD is reported as the mean IENF of these 3 sections per millimeter. SFN symptoms inventory questionnaire. A simple SFN symptoms inventory questionnaire (SIQ) was constructed, based on international guidelines. 13, 14 The SIQ includes 12 inquiries addressing the following aspects: presence of palpitations, flushes, constipation or diarrhea, urination problems (incontinence or hesitation), changes in sweating pattern, restless legs, orthostatic dizziness, dry eyes or mouth, oversensitivity and sheet intolerance of the legs. Items focused on the presence or absence of these symptoms (0 ϭ no symptoms to 12 ϭ maximum number of symptoms).
Vickrey Peripheral Neuropathy Quality-of-Life Instrument-97. The Vickrey Peripheral Neuropathy Qualityof-Life Instrument-97 (PNQoL-97) has the Short-Form 36-Item Health Survey as a generic core, supplemented with specifically neuropathy related questions, resulting in a 97-item scale, with 91 items distributed among 16 multiscale domains and 6 separately scored questions. 15, 16 The domains are physical functioning (11 items), role limitations due to physical health problems (6 items), pain (7) , energy/fatigue (5), upper extremities (6), balance (8), self-esteem (6), emotional well-being (7) , stigma (3), cognitive function (3), role limitations due to emotional problems (3), general health perceptions (7) , sleep (5), social functioning (9), sexual function (2), and health distress (3). 16 Each domain has a scoring range from 0 to 100. A high score indicates better health. For the purpose of the current study, the original PNQoL-97 was translated-back-translated by 2 independent translators into Dutch in accordance with international guidelines. 14 Ambiguous items were discussed until uniformity was obtained on all items. The Vickrey PNQoL-97 physical and mental component summary score (V-PCS, V-MCS) values were calculated. [16] [17] [18] Standard protocol approvals, registration, and patient consent. The study was approved by the medical ethical committees of all participating centers and the CCMO (Central Committee for Human Related Research, identifier number p06.0066L/MEC 05-224). Written informed consent was obtained from all participants before inclusion.
Study design. General aspects. Examination occurred in a comfortable, temperature-controlled room. All participants underwent a standardized interview, neurologic examination, and skin biopsy by a skilled investigator (M.B.). All selected patients were recruited at the department of neurology of the Maastricht University Medical Center (MUMC), The Netherlands. A patient was classified as having SFN symptoms when he or she reported at least 1 of the following symptoms, not otherwise explained: burning pain in extremities, dry mouth or eyes, changes in sweating, flushes, gastrointestinal dysfunction (constipation, diarrhea), cardiac symptoms (palpitation, dizziness on standing up), and urogenital dysfunction (sexual dysfunction, incontinence). Those without any of these symptoms were classified as having no SFN symptoms (patient control group). All patients completed the SIQ and PNQoL-97.
Reliability studies. All biopsies were coded, thus blinding the examiners. The IENFD of all participants at the MUMC was counted by 1 researcher (M.B.). Fifty randomly selected slides (25 patients plus 25 healthy controls) were also analyzed by a second examiner (C.G.F.) (local IENFD interobserver reliability). These 50 slides were recounted by the examiners (interval at least 2 weeks) for the IENFD intraobserver reliability scores of both examiners, without having access to the earlier findings. To determine interobserver reliability between laboratories, examiners at Milan (R.L.), Ferrara (G.D.), and Maastricht (M.B.) each counted 30 arbitrarily selected slides (healthy controls; 10 slides per center, circulating between institutes).
The SIQ was completed twice (interval: 2-4 weeks) to examine its test-retest reliability.
Validity studies. The validity of the IENFD normative values was examined through discriminatory studies with the SIQ and PNQoL-97 domains and component sum scores in the patient group. In particular, we examined whether the normative data would help to discriminate between the obtained scores in these outcome measures that are based on patients' own perception (sarcoidosis patients without SFN symptoms vs those patients with SFN symptoms but normal IENFD scores vs those with SFN symptoms and abnormal IENFD).
Statistical analysis. Data handling and normative values.
Data collection, entry, and management were performed using the Teleform automated processing system, striving to reduce the number of manual data entry errors. 19 All analyses were performed using Stata 10.0 for Windows XP (StataCorp LP, College Station, TX). A value of p Ͻ 0.05 was considered significant.
Normative IENFD reference values were calculated in healthy controls (5th percentile values, corresponding to a chosen specificity of 95%), depending primarily on age and sex. Quantile regression analyses were performed to obtain the normative data. A patient's IENFD was considered to be abnormal if the corresponding value was below the normative data 5th percentile lower limit, because this cutoff value has previously been used. 20 Weight and height were analyzed for possible correlating confounding impact on IENFD normative values.
Reliability studies. Interobserver and intraobserver reliability scores for the IENFD and SIQ test-retest reliability were determined using weighted statistic measures. 21 The weights of the were defined as 1 Ϫ [(i Ϫ j)/(k Ϫ 1)] 2 (i ϭ rows and j ϭ columns of the ratings by 2 observers or by the patients twice in time, k ϭ maximum number of possible ratings).
Validity studies. The discriminative capacity of the obtained IENFD normative values was investigated in 3 subgroups of patients (subgroup A: sarcoidosis patients without SFN symp-toms; subgroup B: sarcoidosis patients with SFN symptoms but normal IENFD values; subgroup C: sarcoidosis patients with SFN symptoms and impaired IENFD scores [Ͻ5th percentile lower limit]) by comparing the obtained scores for SIQ plus PNQoL-97 values in the patient subgroups (analysis of variance with corrections according to Bonferroni multiple comparison tests for continuous variables; 2 test for ordinal variables).
RESULTS General aspects.
Recruitment was performed between January 2006 and June 2008. Skin biopsies were collected in 188 healthy volunteers (Maastricht n ϭ 105, Milan n ϭ 44, Ferrara n ϭ 39), stratifying for age decade and sex (15 men and 15 women per age decade, range 20 -82 years and older, forming 6 age decades). Most volunteers were white (97%).
Between October 2006 and June 2008, 211 patients with sarcoidosis were referred to the MUMC (figure e-1 on the Neurology ® Web site at www. neurology.org). Reasons for exclusion were immunosuppressive treatment (65), comorbidity that could cause neuropathy (30), CNS involvement (11) and large nerve fiber involvement found at neurologic or nerve conduction studies (21) , and inability or unwillingness to attend examination (9) . Eventually, 72 patients met the inclusion criteria and declared willingness to participate. Of these 72 patients, 58 were categorized as having symptoms not otherwise explained and possibly caused by SFN, and 14 were categorized as not having any SFN-related symptoms. All patients mentioned fatigue as one of their main problems. The participants' characteristics are presented in table 1. No complications were encountered in either healthy volunteers or patients due to the skin biopsy.
Normative values. Normative IENFD reference values were calculated in 188 healthy controls. There was a significant age-dependent decrease of IENFD values, with lower scores for men compared with women ( figure 1 ). Height and weight did not have any significant impact on the IENFD scores. The obtained normative scores were subsequently translated per age span and sex for clinical use, using the 5th percentile as a cutoff value (table 2).
Reliability and discriminative validity studies. Good intraobserver reliability values were obtained for both researchers in Maastricht (MB.: weighted ϭ 0.95; C.G.F.: 0.90), with good interobserver scores as well (0.94). There was also a good interobserver reliability between the examiners at the 3 institutes: Maastricht-Milan: weighted ϭ 0.78; Maastricht-Ferrara: 0.83; Milan-Ferrara: 0.91.
In the subgroup of patients with sarcoidosis and possible SFN symptoms (n ϭ 58), 19 patients (32.8%) had impaired IENFD scores. In contrast, all patients without SFN symptoms except 2 (14.3%) had normal IENFD values ( 2 test: p ϭ 0.17). For further discriminative validity studies, we divided the patients with SFN symptoms into those with IENFD being normal and those with IENFD Ͻ5th percentile lower limit, ultimately having 3 subgroups for comparison (subgroup A: sarcoidosis without SFN symptoms, n ϭ 14; subgroup B: sarcoidosis with SFN symptoms, normal IENFD findings, n ϭ 39; subgroup C: sarcoidosis with SFN symptoms and abnormal IENFD values, n ϭ 19). Figure 2 illustrates that more SFN-related symptoms as reported by SIQ are present in patients with abnormal IENFD, with a gradual transition between the 3 subgroups ( 2 test between subgroups: p Ͻ 0.001). Hypersensitivity is reported by 14% in subgroup A, by 69% in subgroup B, and by 79% in subgroup C. Similar differences for symptoms of dry mouth (50%, 72%, 79%) and orthostatic intolerance (36%, 67%, 84%) were found. Presence of SFN symptoms in subgroup A was comparable to that in healthy controls (data not shown). The SIQ demonstrated good test-retest reliability (weighted ϭ 0.88).
A significant discriminative validity was obtained when comparing the results of the PNQoL-97 domains between the 3 subgroups for pain, balance, energy/fatigue, upper extremity function, cognitive functioning, and social functioning. Also, the physical component score of this scale (V-PCS) showed a discriminative trend between the 3 subgroups of patients (table 3) . In general, these PNQoL-97 domains and V-PCS did not significantly differentiate between subgroups B and C, patients with SFN symptoms, but showed a trend of more reduced quality-of-life features in those with abnormal IENFD (table 3) . The remaining domains and V-MCS did not show any difference between the subgroups of patients.
DISCUSSION
In the current study, we described the determination of the largest series of normative distal leg IENFD values, stratified for age and sex. We demonstrated good interobserver/intraobserver reliability and acceptable IENFD validity scores through association with questionnaires. This series of skin biopsies is available for other researchers interested in joining a quality control program and in enlarging their normative reference values. Normative data for IENFD have been reported previously for the same location. 20, [22] [23] [24] Our results differ (lower values) from previous reports on IENFD normative values, which is most probably explained by differences in sample size of healthy controls and in count-ing rules. We found lower IENFD values in men compared with women, and an age-related decrease in IENFD, which is in conformity with these earlier reports. Several neurologic tests have shown decreased function in healthy elderly, such as diminished grip strength, temperature and vibration sensation, and nerve conduction studies. [25] [26] [27] [28] Also, women have been reported to be more sensitive in quantitative sensory testing. 29, 30 On the structural level, agerelated decline is noted too, for example, in Meissner and Pacinian corpuscles. 31, 32 The reasons for agerelated decline and sex differences may be related to differences in hormonal status. 33 Progesterone and its metabolites, for example, stimulate axonal growth and myelinization. Though it is also synthesized in the nervous system, in female rats, it is more abundant because of the gonadal production, and in experimental studies, nerve sprouting, regeneration, and remyelinization are more rapid and more complete in female animals. 34, 35 In our series, we were able to identify one-third of sarcoidosis patients with SFN using only sex-and age-related cutoff IENFD normative values. Our IENFD sensitivity turned out to be lower compared with reported literature findings, which is most probably related to differences in population of patients examined and differences in IENFD cutoff values. [36] [37] [38] We only included patients with pure small fiber-related symptoms and excluded patients with large fiber neuropathy. Others have examined IENFD ϭ intraepidermal nerve fiber density. patients with sensory neuropathy symptoms (thus having thick nerve fiber involvement) and have demonstrated higher sensitivity of reduced IENFD in these patients compared with those with only small nerve fiber involvement. 37, 38 Progression from pure SFN to large fiber involvement in patients over time with further reduction of IENFD in these patients has also been reported, hence underlining the notion of a continuum and progressive disease pattern. 36 The current article addresses discriminatory validity between subgroups of patients with sarcoidosis, translating pathology (small fiber findings in skin biopsy) to impairments (SFN symptoms) and partly to quality-of-life expectations, by demonstrating differences between sarcoidosis patients without SFN symptoms vs those with SFN symptoms but normal IENFD vs those with SFN symptoms and impaired IENFD. Similar findings have been reported in patients with various forms of inflammatory neuropathies. 39 Although not significant, patients with SFN symptoms and impaired IENFD had more physically oriented symptoms, such as more pain, less energy, and more balance problems, and more social dysfunction compared with the other subgroups. Emotional items scores did not differ between subgroups, thus excluding emotional problems as an explanation for patients' dysfunction. Hence, low IENFD contributes to the patients' daily symptoms and physical burden and helps clinicians in understanding its impact in patients with sarcoidosis.
There are some methodologic issues that should be addressed. First, a gold standard for the diagnosis SFN was proposed: the presence of at least 2 abnormal results at clinical, QST, and skin biopsy examinations. 36 However, the validation of this proposition is beyond the scope of the current study. Second, some caution is required when interpreting the results, because the sample sizes of the various subgroups were relatively small. Third, efforts were taken to subdivide the 72 selected patients into 3 subgroups based on a systematic interview focusing on the presence of SFN symptoms. Despite these efforts, patients of the subgroup without any SFN symptoms (subgroup A) reported through the SIQ questionnaire some presence of symptoms, although relatively low compared with the other 2 subgroups of patients ( figure 2) . However, the presence of symptoms in subgroup A was similar to that in healthy controls. Finally, we have not systematically examined whether skin type or occupation might have any influence on IENFD.
The current study presents clinically applicable distal leg IENFD values, supporting previously reported age-and sex-related differences. Validity through association with an SFN-specific and generic quality-of-life questionnaire was acceptable. Hence, IENFD is suggested as an alternative endpoint in future clinical trials in neuropathies, as has been addressed previously. 40 Further study in patients with SFN and validation of a possible gold standard are recommended.
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